ORIGINAL ARTICLE

Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

M J Gizycki¹, K L Hattotuwa^1,2, N Barnes², P K Jeffery¹

¹ Lung Pathology Unit, Imperial College School of Medicine at the Royal Brompton Hospital, London, UK
² London Chest Hospital, London, UK

Correspondence to:
Correspondence to:
Professor P K Jeffery, Lung Pathology Unit, Royal Brompton Hospital, London SW3 6NP, UK;
p.jeffery{at}ic.ac.uk

Background: Inhaled corticosteroids (ICS) markedly reduce bronchial mucosal inflammation in asthma but whether they have an anti-inflammatory effect in airway tissue in chronic obstructive pulmonary disease (COPD) is unknown.

Methods: A study of endobronchial biopsy samples was conducted as part of a double blind, placebo controlled, randomised trial of parallel design. Patients had mild to moderately severe COPD (FEV₁ 25–80% of predicted) and were given 3 months treatment with ICS, fluticasone propionate (FP; 500 µg twice daily, n=14) or placebo (n=10). Biopsy tissue taken at baseline and after treatment was examined by transmission electron microscopy to count the numbers of all ultrastructurally distinct inflammatory cells.

Results: Compared with their baseline values, FP resulted in a significant decrease (on average 65%) in the numbers of mucosal mast cells (median 7.8 (range 1–33) v 2.8 (1–14), p<0.05). The reductive effect of FP held true when the post-treatment values of the placebo and FP groups were compared: 8.8 (1–24) v 2.8 (1–14) (p<0.05). Unexpectedly, there were significantly more neutrophils in the FP than in the placebo group: 4.0 (0–23) v 1.7 (0–8), respectively (p<0.05). There were no alterations to other cell types including mononuclear cells. Symptoms markedly improved in the patients treated with FP for 3 months.

Conclusion: Fluticasone propionate given for 3 months to patients with COPD has selective effects on the inflammatory cells in the bronchial mucosa: the reduction in mast cell numbers may account for the improvement in symptoms over this time.

Keywords: bronchitis; chronic obstructive pulmonary disease; corticosteroids; bronchial biopsy

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Lapperre, T. S., Snoeck-Stroband, J. B., Gosman, M. M.E., Jansen, D. F., van Schadewijk, A., Thiadens, H. A., Vonk, J. M., Boezen, H. M., ten Hacken, N. H.T., Sont, J. K., Rabe, K. F., Kerstjens, H. A.M., Hiemstra, P. S., Timens, W., Postma, D. S., Sterk, P. J., the GLUCOLD (Groningen Leiden Universities Cortico, (2009). Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease: A Randomized Trial. ANN INTERN MED 151: 517-527 [Abstract] [Full Text]  
• Perng, D-W., Tao, C-W., Su, K-C., Tsai, C-C., Liu, L-Y., Lee, Y-C. (2009). Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 33: 778-784 [Abstract] [Full Text]  
• Medicherla, S., Fitzgerald, M. F., Spicer, D., Woodman, P., Ma, J. Y., Kapoun, A. M., Chakravarty, S., Dugar, S., Protter, A. A., Higgins, L. S. (2008). p38{alpha}-Selective Mitogen-Activated Protein Kinase Inhibitor SD-282 Reduces Inflammation in a Subchronic Model of Tobacco Smoke-Induced Airway Inflammation. J. Pharmacol. Exp. Ther. 324: 921-929 [Abstract] [Full Text]  
• Siddiqui, S., Hollins, F., Saha, S., Brightling, C. E. (2007). Inflammatory cell microlocalisation and airway dysfunction: cause and effect?. Eur Respir J 30: 1043-1056 [Abstract] [Full Text]  
• Grootendorst, D. C, Gauw, S. A, Verhoosel, R. M, Sterk, P. J, Hospers, J. J, Bredenbroker, D., Bethke, T. D, Hiemstra, P. S, Rabe, K. F (2007). Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62: 1081-1087 [Abstract] [Full Text]  
• Barnes, N. (2007). Reducing inflammation in COPD: the evidence builds. Thorax 62: 927-928 [Full Text]  
• Suissa, S., McGhan, R., Niewoehner, D., Make, B. (2007). Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 4: 535-542 [Abstract] [Full Text]  
• Parimon, T., Chien, J. W., Bryson, C. L., McDonell, M. B., Udris, E. M., Au, D. H. (2007). Inhaled Corticosteroids and Risk of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 175: 712-719 [Abstract] [Full Text]  
• Soriano, J. B., Sin, D. D., Zhang, X., Camp, P. G., Anderson, J. A., Anthonisen, N. R., Buist, A. S., Burge, P. S., Calverley, P. M., Connett, J. E., Petersson, S., Postma, D. S., Szafranski, W., Vestbo, J. (2007). A Pooled Analysis of FEV1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo. Chest 131: 682-689 [Abstract] [Full Text]  
• Kardos, P., Wencker, M., Glaab, T., Vogelmeier, C. (2007). Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 175: 144-149 [Abstract] [Full Text]  
• Leclerc, O., Lagente, V., Planquois, J-M., Berthelier, C., Artola, M., Eichholtz, T., Bertrand, C. P., Schmidlin, F. (2006). Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 27: 1102-1109 [Abstract] [Full Text]  
• Wouters, E. F. M. (2006). Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several?. Proc Am Thorac Soc 3: 262-269 [Abstract] [Full Text]  
• Bergeron, C., Boulet, L.-P. (2006). Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation.. Chest 129: 1068-1087 [Abstract] [Full Text]  
• Barnes, N. C., Qiu, Y.-S., Pavord, I. D., Parker, D., Davis, P. A., Zhu, J., Johnson, M., Thomson, N. C., Jeffery, P. K., on behalf of the SCO30005 Study Group, (2006). Antiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease. Am. J. Respir. Crit. Care Med. 173: 736-743 [Abstract] [Full Text]  
• Gross, N. J. (2005). Chronic Obstructive Pulmonary Disease Outcome Measurements: What's Important? What's Useful?. Proc Am Thorac Soc 2: 267-271 [Abstract] [Full Text]  
• Brightling, C E, McKenna, S, Hargadon, B, Birring, S, Green, R, Siva, R, Berry, M, Parker, D, Monteiro, W, Pavord, I D, Bradding, P (2005). Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 60: 193-198 [Abstract] [Full Text]  
• Chanez, P., Bourdin, A., Vachier, I., Godard, P., Bousquet, J., Vignola, A. M. (2004). Effects of Inhaled Corticosteroids on Pathology in Asthma and Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 1: 184-190 [Abstract] [Full Text]  
• Belvisi, M. G. (2004). Regulation of Inflammatory Cell Function by Corticosteroids. Proc Am Thorac Soc 1: 207-214 [Abstract] [Full Text]  
• Cazzola, M., Dahl, R. (2004). Inhaled Combination Therapy With Long-Acting {beta}2-Agonists and Corticosteroids in Stable COPD. Chest 126: 220-237 [Abstract] [Full Text]  
• Jeffery, P., Holgate, S., Wenzel, S. (2003). Methods for the Assessment of Endobronchial Biopsies in Clinical Research: Application to Studies of Pathogenesis and the Effects of Treatment. Am. J. Respir. Crit. Care Med. 168: S1-17 [Full Text]  
• (2003). The pharmacoepidemiology of COPD: Recent advances and methodological discussion. Eur Respir J 22: 1s-44s [Full Text]